6533b7d8fe1ef96bd126a470
RESEARCH PRODUCT
Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers
Minna TaipaleToni T. SeppäläUlrika A. HänninenRiku KatainenJan BöhmTomas TanskanenErkki-ville WirtaAnna LepistöJukka-pekka MecklinNetta MäkinenLaura Renkonen-sinisaloKimmo PalinJiri HambergLauri A. AaltonenEsa PitkänenEsa PitkänenLinda M. Forsströmsubject
OncologyMaleCancer ResearchPROGNOSISCD3 ComplexColorectal cancerFEATURESmedicine.medical_treatmentDNA Mutational AnalysisCD8-Positive T-Lymphocytesmedicine.disease_causeTargeted therapyNeoplasms Multiple Primary0302 clinical medicineMUTATIONAL PROCESSESExomeLymphocytesExomeCancer geneticsExome sequencingAged 80 and overMutationMETHYLATIONMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisDNA mismatch repairFemaleMicrosatellite InstabilityKRASColorectal Neoplasmsmedicine.medical_specialtyCARCINOMACD8 Antigens3122 Cancerscancer geneticscolorectal cancersuolistosyövätBiologyArticle03 medical and health sciencesCOLONInternal medicineKRASmedicineHumansSIGNATURESIMMUNOSCOREAgedDNA-analyysiMicrosatellite instabilitymedicine.diseaseColorectal cancerCase-Control StudiesMutationdescription
BACKGROUND: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches. METHODS: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion and mutation profile in both lesions of an individual. RESULTS: The tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden. CONCLUSIONS: The study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the need to evaluate both tumours of a synchronous pair for optimised targeted therapy. Peer reviewed
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-03-21 | British Journal of Cancer |